Can Children Use Pataday Drops?
Yes, children aged 2 years and older can safely use Pataday (olopatadine) ophthalmic drops for allergic conjunctivitis. 1
FDA-Approved Age Indications
The FDA label for Pataday ophthalmic solution explicitly states that children 2 years of age and older may use this medication, with dosing of 1 drop in the affected eye(s) once daily. 1 This represents the official regulatory approval for pediatric use.
Guideline Support for Pediatric Use
Multiple clinical practice guidelines support the use of olopatadine eye drops in children:
For children ≥3 years: Olopatadine is approved and recommended as a dual-action agent (antihistamine and mast cell stabilizer) for treating allergic conjunctivitis symptoms. 2
For children ≥7 years: Expert consensus guidelines specifically recommend topical antihistamine eyedrops including olopatadine as second-line treatment for dupilumab-related ocular surface disorders and other allergic eye conditions. 3
Broader pediatric context: Olopatadine is listed among topical ophthalmic preparations appropriate for people of all ages when treating ocular allergy symptoms, with specific approval for children >3 years at a dosing frequency of 2 times daily for up to 4 months. 3
Safety Profile in Children
The safety of olopatadine in pediatric populations has been well-established:
A 6-week randomized, double-masked safety study in 126 children and adolescents aged 3-17 years found no clinically relevant treatment-related changes in visual acuity, intraocular pressure, slit-lamp assessments, fundus examinations, or cardiovascular parameters. 4
All adverse events reported were mild or moderate, with the most common being local irritation at the site of administration. 3, 4
Comparative studies in children with seasonal allergic conjunctivitis demonstrated that olopatadine was more effective than cromolyn sodium and levocabastine while maintaining excellent tolerability. 5
Clinical Efficacy in Pediatric Patients
Research specifically evaluating children has demonstrated:
Significant reduction in ocular itching, redness, eyelid swelling, and other allergic symptoms in children aged 4-11 years with seasonal allergic conjunctivitis. 5
A Hungarian study of 37 children (average age 8.8-10.5 years) with ragweed allergy showed dramatic improvement in discomfort, itching, foreign body sensation, tearing, and redness after 2 weeks of twice-daily olopatadine treatment. 6
Environmental challenge studies including children aged 11-17 years confirmed efficacy and tolerability comparable to adult populations. 7
Important Caveats
For children under 2 years: The medication is not approved, and a physician should be consulted before use. 1
For children under 7 years with certain conditions: When treating dupilumab-related ocular surface disorders, ophthalmology consultation is recommended before initiating antihistamine eyedrops, as this population may have limited benefit and should not have referral to specialists delayed. 3
Dosing Considerations
Standard dosing: One drop in the affected eye(s) once daily for children ≥2 years. 1
Frequency: No more than once per day. 1
Drug interactions: If using other ophthalmic products, wait at least 5 minutes between each product. 1
Duration: Studies have demonstrated safety for up to 4 months of continuous use in children. 3